-
Uncategorized1 week ago
Trustworthy AI in clinical oversight
AI can accelerate clinical work and preserve traceability, but only if users can trust it. Read More
-
Uncategorized1 week ago
6 FDA Decisions To Watch in Q2 2026
6 FDA Decisions To Watch in Q2 2026
-
Uncategorized1 week ago
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
-
Uncategorized1 week ago
Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts
Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists...
-
Uncategorized1 week ago
Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025
Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.Read...
-
Uncategorized1 week ago
StockWatch: Wave Plummets 50% on Obesity Data
Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed...
-
Uncategorized1 week ago
Engineering macrophage-targeted trispecific immune cell engagers for tumor immunotherapy
Nature Biotechnology, Published online: 30 March 2026; doi:10.1038/s41587-026-03104-5 Immune cell engagers (ICEs) have emerged as a promising strategy for cancer immunotherapy, but their efficacy in solid...
-
Uncategorized1 week ago
Kailera plans IPO for Phase 3 obesity drug from Hengrui
Kailera plans IPO for Phase 3 obesity drug from Hengrui
-
Uncategorized1 week agoSTAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Alex Zhavoronkov, CEO of Insilico Medicine, can’t stop complimenting Eli Lilly. “Lilly is better in AI than Insilico, and no other company is better in AI...
-
Uncategorized1 week ago
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
